News for Corcept Therapeutics Incorporated (CORT)

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts.

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial panic over […]

Corcept Therapeutics (CORT) to present pivotal Phase 3 ROSELLA trial data at ASCO 2025. Study focuses on relacorilant with nab-paclitaxel in platinum-re

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinol

Market Analysis by covering: Corcept Therapeutics Incorporated, AbbVie Inc, DBV Technologies, ACELYRIN Inc. Read 's Market Analysis on Investing.com

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate CORT stock a Strong Buy.

We recently published a list of 10 Firms Kick Off Trading Week Stronger.

We recently published a list of 10 Firms Kick Off Trading Week Stronger. In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other firms that kicked off the trading week stronger. The stock market began the trading week on a mixed note as investors continued to […]

U.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 100 points on Monday. The Dow traded up 0.30% to 41,710.68 while the NASD...

U.S. stocks were mixed, with the Nasdaq Composite falling over 1% on Monday. Shares of Mr. Cooper Group Inc. COOP rose sharply during Monday's session after th...

U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 300 points on Monday. Following the market opening Monday, the Dow traded do...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer a

PR NewswireNEW YORK, March 17, 2025 NEW YORK, March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Thera

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinol

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinol

PR NewswireNEW YORK, March 3, 2025 NEW YORK, March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeu

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinol

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025.

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2024 financial results and provide a corporate upd